

Resource Summary Report

Generated by RRID on Aug 1, 2026

EGF Receptor, Custom formulation (BSA/Carrier Free)

RRID:AB_2895042

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4267BF, RRID:AB_2895042

Antibody Information

URL: http://antibodyregistry.org/AB_2895042

Proper Citation: Cell Signaling Technology Cat# 4267BF, RRID:AB_2895042

Target Antigen: EGF Receptor

Host Organism: rabbit

Clonality: monoclonal

Comments: Custom formulation (BSA/Carrier Free)

Antibody Name: EGF Receptor, Custom formulation (BSA/Carrier Free)

Description: This monoclonal targets EGF Receptor

Target Organism: Human, Monkey, Mouse

Clone ID: D3881

Antibody ID: AB_2895042

Vendor: Cell Signaling Technology

Catalog Number: 4267BF

Record Creation Time: 20250820T022517+0000

Record Last Update: 20250820T133235+0000

Ratings and Alerts

No rating or validation information has been found for EGF Receptor, Custom formulation (BSA/Carrier Free).

No alerts have been found for EGF Receptor, Custom formulation (BSA/Carrier Free).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Yu J, et al. (2025) PIN1 serves as a prognostic and therapeutic biomarker in lung adenocarcinoma. Functional & integrative genomics, 25(1), 121.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Cancer research, OF1.

Thielen N, et al. (2025) High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS G12D Mutated CRC. bioRxiv : the preprint server for biology.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell reports. Medicine, 6(8), 102253.

Ngalula S, et al. (2025) TNF- α -Driven Changes in Polarized EGF Receptor Trafficking Facilitate Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling From the Apical Surface of MDCK Epithelial Cells. Traffic (Copenhagen, Denmark), 26(4-6), e70005.

Ali H, et al. (2025) Neuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma. Cell reports, 44(10), 116342.

Hsu HE, et al. (2025) Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures. Molecular systems biology, 21(11), 1547.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell reports. Medicine, 6(2), 101929.

Gu D, et al. (2025) Stress-induced pro-inflammatory glioblastoma stem cells secrete TNFAIP6 to enhance tumor growth and induce suppressive macrophages. Developmental cell.

Zacharias NM, et al. (2025) Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. *Molecular cancer therapeutics*.

Huang YY, et al. (2025) EGFR phosphorylates DNAJB1 to suppress α -synuclein aggregation in Parkinson's disease. *NPJ Parkinson's disease*, 11(1), 157.

Liu G, et al. (2025) ILC2 instructs neural stem and progenitor cells to potentiate neurorepair after stroke. *Neuron*, 113(11), 1741.

Emelianov EA, et al. (2025) Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. *International journal of molecular sciences*, 27(1).

Zutshi N, et al. (2024) Cbl and Cbl-b ubiquitin ligases are essential for intestinal epithelial stem cell maintenance. *iScience*, 27(6), 109912.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC β in lung adenocarcinoma. *Cell reports*, 43(12), 115026.

Tran TTT, et al. (2024) Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer. *EBioMedicine*, 108, 105356.